Viewing Study NCT02799602

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:45 AM
Ignite Modification Date: 2026-03-03 @ 4:27 AM
Study NCT ID: NCT02799602
Status: COMPLETED
Last Update Posted: 2025-12-04
First Post: 2016-06-06
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Sponsor: Bayer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Hormone-sensitive Prostate Cancer View
Keywords: